Theravance Biopharma R&d Ip, LLC

Alfasigma S.p.a.

Christopher Noel Barnes

Edmund J Moran

Glenn D Crater

Srikanth Pendyala

Giuseppe Claudio Viscomi

Maria Grimaldi

Cecilia Renzulli

Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEVless than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEVand trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.

Methods for treating chronic obstructive pulmonary disease

The present invention relates to methods and pharmaceutical compositions for treatment of all symptoms of gastroparesis in a human patient, the method comprising administering to the human patient between about 0.5 mg/day to about 30 mg/day, about 0.5 mg/day to about 15 mg/day, about 0.5 mg/day to about 5 mg/day, or about 5 mg/day, of velusetrag or a pharmaceutically-acceptable salt thereof.

Methods of treating symptoms of gastroparesis using velusetrag

Growing community of inventors

San Francisco, CA, United States of America

Christopher Noel Barnes